Peter Rhode
CIK 1866276 · View on SEC EDGAR ↗
First SEC filing: July 19, 2021 · Latest: July 19, 2021
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| July 22, 2021 | HCWB | P | 12,500 | $8.00 | $100,000 | 46,785 Direct | +36.46% | Acquired | -99.9% (price as of 2026-08-18) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Dec. 11, 2023 | HCWB | Stock Option (Right to Buy) | Common Stock (14,000) | $0.14 | Dec. 19, 2029 | 14,000 | Disposed |
| Nov. 17, 2023 | HCWB | Stock Option Grant (Right to Buy) | Common Stock (15,000) | $0.14 | Dec. 19, 2029 | 15,000 | Disposed |
| Jan. 14, 2022 | HCWB | Stock Option Grant (Right to Buy) | Common Stock (1,714) | $0.21 | Dec. 22, 2030 | 1,714 | Disposed |
| Jan. 14, 2022 | HCWB | Stock Option Grant (Right to Buy) | Common Stock (1) | $0.14 | Dec. 19, 2029 | 1 | Disposed |
| Sept. 8, 2021 | HCWB | Stock Option (Right to Buy) | Common Stock (20,000) | $4.31 | Sept. 7, 2031 | 20,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 3 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
HCWB
Ph.D. Chief Scientific Officer and Vice President of Clinical Operations| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2022 | $238,404 | — | — | — | — | — | $10,166 | $248,570 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.